A new study published The Journal of Asthmaassessed that comparative effectiveness of low-dose budesonide inhalation suspension (BIS) versus oral montelukast (MON) in managing asthma control among children with mild asthma. This retrospective study analyzed claims from Koreas national health insurance database for children (2-17 years) with mild asthma (GINA 1 or 2) who initiated BIS or MON during 2015. Adherence, persistence, asthma control, asthma-related health-care resource utilization, and costs were evaluated. Overall, 26,052 children were identified for unmatched population and 2,290 were identified for matched populations. It was found that medication adherence, measured by proportion of days covered, was low for both cohorts, but significantly higher for MON versus BIS. Time to loss of persistence was longer for MON. The mean number of post-index asthma-related office visits was 6.6 for BIS versus 8.3 for MON. In addition, greater proportion of patients in the BIS cohort had an asthma exacerbation-related office visit than the MON cohort. On the other hand, asthma-related total health-care costs were comparatively higher with MON.From the findings, it was concluded that patients who received montelukast had better adherence, a longer time to loss of persistence and were less likely to experience an exacerbation-related office visit in the post-index period than BIS patients.